Synonym
DPC 681; DPC-681; DPC681; DPH 153893; DPH-153893; DPH153893;
IUPAC/Chemical Name
(S)-2-(N-((2S,3R)-4-((3-amino-N-isobutylphenyl)sulfonamido)-3-hydroxy-1-phenylbutan-2-yl)-2-((3-fluorobenzyl)amino)acetamido)-3,3-dimethylbutanamide
InChi Key
VAXRCFUMOHKDCQ-RKKDRKJOSA-N
InChi Code
InChI=1S/C35H48FN5O5S/c1-24(2)22-40(47(45,46)29-16-10-15-28(37)19-29)23-31(42)30(18-25-11-7-6-8-12-25)41(33(34(38)44)35(3,4)5)32(43)21-39-20-26-13-9-14-27(36)17-26/h6-17,19,24,30-31,33,39,42H,18,20-23,37H2,1-5H3,(H2,38,44)/t30-,31+,33+/m0/s1
SMILES Code
CC(C)(C)[C@@H](C(N)=O)N(C(CNCC1=CC=CC(F)=C1)=O)[C@@H](CC2=CC=CC=C2)[C@H](O)CN(S(=O)(C3=CC=CC(N)=C3)=O)CC(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
669.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kaltenbach RF 3rd, Trainor G, Getman D, Harris G, Garber S, Cordova B, Bacheler L, Jeffrey S, Logue K, Cawood P, Klabe R, Diamond S, Davies M, Saye J, Jona J, Erickson-Viitanen S. DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8. PubMed PMID: 11600351; PubMed Central PMCID: PMC90777.
2: Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E, Brennan JM, Benedek IH, Jolley S, Gilbert D, Wang L, Lee FW, Gan LS. Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos. 2003 Sep;31(9):1170-5. PubMed PMID: 12920173.
3: Solon EG, Balani SK, Luo G, Yang TJ, Haines PJ, Wang L, Demond T, Diamond S, Christ DD, Gan LS, Lee FW. Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography. Drug Metab Dispos. 2002 Nov;30(11):1164-9. PubMed PMID: 12386120.
4: Randolph JT, DeGoey DA. Peptidomimetic inhibitors of HIV protease. Curr Top Med Chem. 2004;4(10):1079-95. Review. PubMed PMID: 15193140.
